Tags

Type your tag names separated by a space and hit enter

[GSK-3beta: a central kinase for neurodegenerative diseases?].
Med Sci (Paris). 2010 May; 26(5):516-21.MS

Abstract

Neurodegenerative diseases are more and more prevalent in our aging societies. There is strong evidence that glycogen synthase kinase (GSK)-3b plays a crucial role in Alzheimer's disease (AD). Indeed, it is involved in the regulation of the two major neuropathological hallmarks present in the brains of AD patients. Interestingly, the kinase has been implicated in multiple cellular processes and linked with the pathogenesis and neuronal loss in several neurodegenerative diseases, including Parkinson's and Huntington's diseases, in which abnormally elevated levels of GSK-3b activity have been reported. In this review, we will provide an overview of the current data pointing out the convergent role of GSK-3b in the neuropathological pathways of these diseases. We will also discuss the rationale for the development of specific inhibitors with therapeutic potentials for such devastating human diseases.

Links

Publisher Full Text

Authors+Show Affiliations

Petit-Paitel A
Institut de pharmacologie moléculaire et cellulaire, route des Lucioles, Sophia Antipolis, Valbonne, France. petit@ipmc.cnrs.fr

MeSH

Alzheimer DiseaseAmyloid beta-Protein PrecursorApoptosisBrainCarrier ProteinsGlycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaHumansLewy BodiesMitochondriaModels, NeurologicalNerve Tissue ProteinsNeurodegenerative DiseasesNeurofibrillary TanglesParkinson DiseasePhosphorylationPlaque, AmyloidPresenilinsProtein Kinase InhibitorsProtein Processing, Post-Translationalalpha-Synucleintau Proteins

Pub Type(s)

Journal Article
Review

Language

fre

PubMed ID

20510151

Citation

Petit-Paitel, Agnès. "[GSK-3beta: a Central Kinase for Neurodegenerative Diseases?]." Medecine Sciences : M/S, vol. 26, no. 5, 2010, pp. 516-21.
Petit-Paitel A. [GSK-3beta: a central kinase for neurodegenerative diseases?]. Med Sci (Paris). 2010;26(5):516-21.
Petit-Paitel, A. (2010). [GSK-3beta: a central kinase for neurodegenerative diseases?]. Medecine Sciences : M/S, 26(5), 516-21. https://doi.org/10.1051/medsci/2010265516
Petit-Paitel A. [GSK-3beta: a Central Kinase for Neurodegenerative Diseases?]. Med Sci (Paris). 2010;26(5):516-21. PubMed PMID: 20510151.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [GSK-3beta: a central kinase for neurodegenerative diseases?]. A1 - Petit-Paitel,Agnès, PY - 2010/6/1/entrez PY - 2010/6/1/pubmed PY - 2010/8/12/medline SP - 516 EP - 21 JF - Medecine sciences : M/S JO - Med Sci (Paris) VL - 26 IS - 5 N2 - Neurodegenerative diseases are more and more prevalent in our aging societies. There is strong evidence that glycogen synthase kinase (GSK)-3b plays a crucial role in Alzheimer's disease (AD). Indeed, it is involved in the regulation of the two major neuropathological hallmarks present in the brains of AD patients. Interestingly, the kinase has been implicated in multiple cellular processes and linked with the pathogenesis and neuronal loss in several neurodegenerative diseases, including Parkinson's and Huntington's diseases, in which abnormally elevated levels of GSK-3b activity have been reported. In this review, we will provide an overview of the current data pointing out the convergent role of GSK-3b in the neuropathological pathways of these diseases. We will also discuss the rationale for the development of specific inhibitors with therapeutic potentials for such devastating human diseases. SN - 0767-0974 UR - https://www.unboundmedicine.com/medline/citation/20510151/[GSK_3beta:_a_central_kinase_for_neurodegenerative_diseases]_ L2 - http://publications.edpsciences.org/10.1051/medsci/2010265516 DB - PRIME DP - Unbound Medicine ER -